ScoreWhy is Concord Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.41%
- Poor long term growth as Net Sales has grown by an annual rate of 14.78% and Operating profit at 2.53% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.56
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Concord Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Concord Drugs
34.88%
0.79
44.36%
Sensex
-1.65%
-0.12
13.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.78%
EBIT Growth (5y)
2.53%
EBIT to Interest (avg)
1.56
Debt to EBITDA (avg)
5.56
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.90
Tax Ratio
28.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.64%
ROE (avg)
1.92%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
93
Industry P/E
37
Price to Book Value
2.03
EV to EBIT
34.88
EV to EBITDA
24.40
EV to Capital Employed
1.81
EV to Sales
1.41
PEG Ratio
0.68
Dividend Yield
NA
ROCE (Latest)
5.20%
ROE (Latest)
2.18%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend35What is working for the Company
NET SALES(Q)
At Rs 20.95 cr has Grown at 53.93%
PBT LESS OI(Q)
Highest at Rs 1.54 cr.
PAT(Q)
Highest at Rs 1.11 cr.
PBDIT(Q)
Highest at Rs 2.29 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 10.93%
EPS(Q)
Highest at Rs 0.84
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Concord Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1.54 cr has Grown at 862.50%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Net Sales - Quarterly
At Rs 20.95 cr has Grown at 53.93%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1.54 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1.11 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 2.29 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 10.93%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.84
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
